Utilization Patterns and Net Direct Medical Cost to Medicaid of Irritable Bowel Syndrome

Bradley C. Martin; Rahul Ganguly; Sandhya Pannicker; Feride Frech; Victoria Barghout


Curr Med Res Opin. 2003;19(8) 

In This Article


In summary, this study confirms the substantial economic burden that IBS imposes on the health care system and affirms the increased recognition of IBS as a complex medical disorder with a heavy comorbidity burden. IBS in the Medicaid population is associated with significant increases in health care resource utilization. The greater unadjusted and adjusted net expenditures for IBS cases versus matched controls generally were unaffected by the variables of sex and race and were highest for those aged 41-65. The disparity between the treated prevalence rates in our study and the population-based survey estimates suggests that diagnostic criteria and treatment guidelines are used inconsistently in clinical practice and that many patients with IBS may not seek treatment from health care providers. Future research should be directed at assessing the impact the newest IBS therapies and the treatment guidelines have on health system costs and patient outcomes.

This study was presented, in part, at the following two conferences:
2002 Digestive Disease Weekly (DDW) Conference, San Francisco, CA, May 22, 2002; and 2001 American College of Gastroenterology Annual Meeting, Las Vegas, NV, October 23, 2001


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.